Cargando…

Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL

Serum soluble interleukin-2 receptor (sIL-2R) is a practical tumor marker that is elevated in hematogenous tumors. The purpose of this study was to determine the usefulness of serum sIL-2R for differentiating among malignant brain tumors, including primary central nervous system lymphoma (PCNSL) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	MITOBE, Yuta, MATSUDA, Ken-ichiro, SONODA, Yukihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japan Neurosurgical Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072886/ https://www.ncbi.nlm.nih.gov/pubmed/36682790 http://dx.doi.org/10.2176/jns-nmc.2022-0179

Ejemplares similares

Serum soluble interleukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions
por: Murakami, Jun, et al.
Publicado: (2019)

Serum Levels of Soluble Interleukin-2 Receptor in Pulmonary Tuberculosis
por: Choi, Soo Jeon, et al.
Publicado: (1990)

Treatment outcome and prognostic factors in PCNSL
por: Niparuck, Pimjai, et al.
Publicado: (2019)

Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
por: Patrij, Katrin, et al.
Publicado: (2011)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

Changes in vascular supply pattern associated with growth of nonfunctioning pituitary adenomas
por: Ito, Miiko, et al.
Publicado: (2022)

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA (R/R PCNSL/SCNSL) AND PRIMARY VITREORETINAL LYMPHOMA (PVRL)
por: Soussain, Carole, et al.
Publicado: (2022)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis
por: Kobayashi, Yuta, et al.
Publicado: (2021)

Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.
por: Marino, P., et al.
Publicado: (1990)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Soluble interleukin-2 receptor α and interleukin-2 serum levels in patients with basal cell carcinoma
por: Sobjanek, Michal, et al.
Publicado: (2016)

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL
por: Ohka, Fumiharu, et al.
Publicado: (2021)

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma
por: Boyano, M D, et al.
Publicado: (2000)

Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
por: Nakata, B., et al.
Publicado: (1998)

The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis
por: Chen, Xiaohong, et al.
Publicado: (2020)

Different imaging patterns of PCNSL and IVL: a case report
por: Jeon, Seung-Ho, et al.
Publicado: (2019)

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
por: Baraniskin, Alexander, et al.
Publicado: (2021)

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.
por: Pizzolo, G., et al.
Publicado: (1987)

Delayed acute subdural hematoma treated with endoscopic procedure: A case report
por: Kuge, Atsushi, et al.
Publicado: (2020)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma
por: Wodok-Wieczorek, Karolina, et al.
Publicado: (2018)

Is there an association between serum soluble interleukin-2 receptor levels and syndrome severity in persistent Complex Regional Pain Syndrome?
por: Mangnus, Thomas J P, et al.
Publicado: (2023)

Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy
por: Nukui, Akinori, et al.
Publicado: (2017)

GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
por: Takashima, Yasuo, et al.
Publicado: (2020)

Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
por: Lissoni, P., et al.
Publicado: (1989)

Reduced Serum Levels of Soluble Interleukin-15 Receptor α in Schizophrenia and Its Relationship to the Excited Phenotype
por: He, Yi, et al.
Publicado: (2022)

Elevation of soluble interleukin-2 receptor levels in nasal allergy
por: Hisamatsu, K., et al.
Publicado: (1995)

Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study
por: Kohsari, Maryam, et al.
Publicado: (2020)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)
por: Gomes Candido Reis, Diego, et al.
Publicado: (2021)

Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis
por: Miyata, Jun, et al.
Publicado: (2020)

Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab
por: Vilaiyuk, Soamarat, et al.
Publicado: (2019)

Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4
por: Zekri, Abdel-Rahman N, et al.
Publicado: (2010)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Correlation of serum tumor necrosis factor-alpha, interleukin-4 and soluble interleukin-2 receptor levels with radiologic and clinical manifestations in active pulmonary tuberculosis.
por: Kart, Levent, et al.
Publicado: (2003)

Possible Clinical Significance of Serum Soluble Interleukin-2 Receptor Level in Primary Bone Lymphoma: Two Case Reports
por: Yabe, Hiroki, et al.
Publicado: (2011)

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment‐resistant major depressive disorder
por: Yamasaki, Katsuhiko, et al.
Publicado: (2020)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_umjom66v9knvjnqfs3bimovtpn